Harmony Biosciences HRMY
$32.59 −$0.39 (-1.18%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $32.59 0.00%
Open$32.68
Prev close$32.98
Day range$32.51 – $33.43
Volume582.6K
Market cap$1.91B
P/E (TTM)10.8
Dividend yield–
Earnings
Average move on report day±7.3%last 16 reports
Closed higher10 of 1663% of the time
Best reaction+19.4%
Worst reaction-11.1%
Stock move on the day after each report
| Quarter | Report date | Timing | Implied move | Actual move | Versus implied |
|---|---|---|---|---|---|
| 2026/Q3 | 4 Nov 2026 | Pre Market | ±15.1% | -7.04% | Within range |
| 2026/Q2 | 4 Aug 2026 | Pre Market | ±16.8% | +8.93% | Within range |
| 2026/Q1 | 7 May 2026 | Pre Market | ±14.0% | -4.15% | Within range |
| 2025/Q4 | 24 Feb 2026 | Pre Market | ±14.0% | +4.91% | Within range |
| 2025/Q3 | 4 Nov 2025 | Pre Market | ±11.0% | +4.74% | Within range |
| 2025/Q2 | 5 Aug 2025 | Pre Market | ±18.0% | -1.69% | Within range |
| 2025/Q1 | 6 May 2025 | Pre Market | ±13.5% | +6.98% | Within range |
| 2024/Q4 | 25 Feb 2025 | Pre Market | ±13.5% | +8.16% | Within range |
| 2024/Q3 | 29 Oct 2024 | Pre Market | ±16.7% | +16.06% | Within range |
| 2024/Q2 | 6 Aug 2024 | Pre Market | ±23.3% | +6.18% | Within range |
| 2024/Q1 | 30 Apr 2024 | Pre Market | ±13.5% | +5.68% | Within range |
| 2023/Q4 | 22 Feb 2024 | Pre Market | ±17.4% | -4.70% | Within range |
| 2023/Q3 | 31 Oct 2023 | Pre Market | ±14.7% | +19.43% | Bigger than priced |
| 2023/Q2 | 1 Aug 2023 | Pre Market | ±18.0% | -3.90% | Within range |
| 2023/Q1 | 2 May 2023 | Pre Market | ±15.0% | +2.41% | Within range |
| 2022/Q4 | 21 Feb 2023 | Pre Market | – | -11.08% | – |
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$268.92M+12.3% YoY
Operating profit$54.20M-17.2% YoY
Net profit$48.20M-5.2% YoY
Diluted EPS$0.81-6.9% YoY
Free cash flow$76.69M-29.4% YoY
Operating cash flow$76.69M
Revenue, last 8 quarters
Net profit, last 8 quarters
Profitability & balance sheet
Gross margin74.0%
Operating margin22.2%
Net margin18.1%
Return on equity18.7%
Return on assets13.3%
Return on invested capital15.1%
Current ratio3.44
Liabilities / assets27.5%
Cash & investments$771.14M
Total debt$149.10M
Net cash (debt)$622.03M
Free cash flow / sales32.6%
No comments yet — be the first to weigh in on HRMY.
Sign in to join the discussion.